See how blood-based joint care is prepared

Know what the clinic prepares

Platelets are small blood pieces involved in clotting. Plasma is the pale liquid that carries them through your body.

A blood draw from your arm comes first. The clinic then spins it to gather more clotting pieces for the treatment.

The prepared blood is then used near the sore joint during the planned clinic visit. It isn't new cartilage or a new joint surface.

Keep comfort separate from joint repair

Walking can improve while an X-ray still looks the same. Less soreness can also help with reaching, dressing, or sleep.

Cartilage is the smooth covering on bone ends inside a joint. It has little blood flow, so it doesn't heal like a skin cut.

Set a goal you can check before choosing treatment. Walking farther or sleeping longer tells you more than a broad repair claim.

Decide how you'll check for improvement

Choose one activity that the joint limits now. You might use stairs, dressing, or the distance you can walk.

Note your limit before care and check the same task later. If it hasn't changed after the agreed time, you can discuss a different choice.

People often ask whether this blood treatment works for everyone. It may ease symptoms for some people, but it can't promise the same answer for you.

Sources

1. A concise review of mesenchymal stem cells for functional cartilage tissue engineering sets out the underlying problem: articular cartilage is avascular and has very limited intrinsic repair capacity, which is precisely why engineered and cell-based approaches are being pursued - and why building tissue that matches native articular cartilage in composition and mechanical function remains an unsolved engineering problem rather than a delivered clinical product.

   Tan AR, et al. — Concise Review: Mesenchymal Stem Cells for Functional Cartilage Tissue Engineering: Taking Cues from Chondrocyte-Based Constructs.. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.16-0271.

2. Arnold Caplan, who NAMED mesenchymal stem cells more than 25 years earlier, argued in Stem Cells Translational Medicine that the name should be changed. His stated reason is exactly the marketing problem: because MSCs are called 'stem cells', patients infer they will receive direct medical benefit, imagining the cells will differentiate into regenerating tissue-producing cells - and hundreds of clinics and trials now use human MSCs with very few focusing on the in vitro multipotential capacities the name refers to.

   Caplan AI, et al. — Mesenchymal Stem Cells: Time to Change the Name!. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.17-0051.

3. A randomized, double-blind, placebo-controlled trial in a Japanese population tested leukocyte-POOR PRP specifically in mild-to-moderate knee OA WITH joint effusion or bone marrow lesions - i.e. a selected inflammatory phenotype rather than all comers. Recorded here because phenotype selection, not the product, is the most plausible explanation for why PRP trials disagree with one another.

   Yoshioka T, et al. — The Effectiveness of Leukocyte-Poor Platelet-Rich Plasma Injections for Symptomatic Mild to Moderate Osteoarthritis of the Knee With Joint Effusion or Bone Marrow Lesions in a Japanese Population: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.. The American journal of sports medicine, 2024. DOI: 10.1177/03635465241263073.

4. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

5. The phase II trial of lorecivivint (SM04690), an intra-articular CLK2/DYRK1A inhibitor and Wnt-pathway modulator, is the reference for how a genuine disease-modifying osteoarthritis DRUG is developed - defined molecule, defined target, dose-ranging, radiographic endpoints - which is the standard against which an unstandardised autologous injectate should be read.

   Yazici Y, et al. — Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.. Arthritis & rheumatology (Hoboken, N.J.), 2020. DOI: 10.1002/art.41315.